265 results about "Leptin" patented technology

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.

The invention provides tools for management of patients diagnosed with ankylosing spondylitis and prior to the initiation of therapy with an anti-TNFalpha agent. The tools are specific markers and algorithms of predicting response to therapy based on standard clinical primary and secondary end-points using serum marker concentrations. In one embodiment the baseline level of leptin or osteocalcin is used to predict the response at Week 14 after the initiation of therapy. In another embodiment, the change in a serum protein biomarker after 4 weeks of therapy is used such as complement component 3.

Modified human leptin polypeptides and uses thereof are provided.

The present invention provides fusion proteins comprising leptin and a second protein. The presence of the second protein provides increased biological activity and/or increased half-life in vivo. The present invention also provides human, canine and feline leptin molecules fused to peptides, antibodies or antibody fragments which enhances the abilities of the leptin molecules to transport through the blood-brain-barrier (BBB). The present invention also provides fusion proteins further comprising a peptide agonist that is capable of binding to and stimulate one, two or all three of the following receptors: GLP-1 receptor, Glucagon receptor, and GIP receptor. Also disclosed is a method of production such fusion proteins through recombinant technologies. The invention further discloses a pharmaceutical composition comprising one of the fusion proteins as an active intergradient as well as a method for using such a pharmaceutical composition to treat diseases in dogs, cats and humans.

The present invention relates to a non-human vertebrate animal model displaying an alteration in fat metabolism or in the sensitivity towards leptin or insulin, which model bears a mutation in the gene encoding the spinster like 1 protein (Spinl1). The invention also relates to mutant Spinl1 proteins and nucleic acid sequences encoding these proteins. Furthermore, the invention relates to the use of the non-human vertebrate animal model for the identification of diagnostic markers, or as a model for studying the molecular and physiological mechanisms associated with an alteration in fat metabolism or an alteration in the sensitivity towards leptin or insulin, or for the identification and testing of agents useful in the prevention, amelioration, or treatment of the above conditions. Agents, pharmaceutical compositions, and methods for treating the above conditions are likewise described, as are methods for identifying said agents.

Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol or prodrugs thereof. The compositions may also be in the form of a controlled release formulation. Methods are also provided for use of estradiol metabolites to treat or prevent insulin resistance, vascular endothelial dysfunction, hyperlipidemia, hypertension, diabetic nephropathy, proteinuria and reducing leptin levels. In addition, the methods provide a method of stabilizing glucose levels. These treatments may be used in either gender because of their lack of a feminizing estrogenic effect.

The present invention relates to methods for prevention and/or treatment of metabolic disorders, post-menopausal obesity and conditions associated with high fat diet consumption including, obesity, body weight gain, fat mass formation, bone mineral content reduction, white adipose tissue weight gain, increased cholesterol levels, increased leptin levels, insulin resistance, type II diabetes, increased blood glucose levels, inflammatory diseases, cardiovascular diseases, fatty liver condition (accumulation of fat in the liver), decreased uncoupling protein-1 (UCP-1) levels and increased lipogenesis.

A porcine adipocyte-specific polypeptide, termed leptin, is expressed in the fat tissue of pigs. Expression may be altered in over fat pigs, or expression may be in the form of a protein of lesser biological activity relative to that of leaner pigs. The porcine adipocyte polypeptide, DNA and RNA molecules coding therefor, methods for its preparation, and antibodies specific for the polypeptide are disclosed. Methods for determining the susceptibility of a pig to fat deposition are based on measuring the levels of the porcine adipocyte polypeptide in a biological fluid or tissue extract or by measuring mRNA encoding the porcine adipocyte polypeptide in cells of the subject. Methods of evaluating an agent related to the deposition of fat in swine comprise contacting the agent with an adipocyte in vitro and measuring the amount of the porcine adipocyte polypeptide or mRNA that is produced by the adipocyte. Methods of limiting fat deposition include administering porcine leptin or porcine leptin DNA, and methods of regulating intake include administering porcine leptin, porcine leptin DNA, or an antibody directed against porcine leptin.

The invention provides a method for determining the presence of leptin in a sample.

The invention relates to the field of microorganisms and discloses lactobacillus plantarum with a weight reducing function and application thereof. The lactobacillus plantarum 1701 strain is separatedfrom a yogurt powder sample collected from rural areas of Shigatse in the Tibet Autonomous Region. The strain is preserved in the China General Microbiological Culture Collection Center on October 23, 2019, and the microorganism has the preservation number of CGMCC NO.18728. The lactobacillus plantarum 1701 has excellent tolerance and adhesion, can remarkably reduce the weight of a rat, reduce fat accumulation in a body, reduce the viscera ratio and body fat ratio, reduce the leptin level and reduce blood lipid and can be used in medicines, health-protecting products and health foods for preventing and treating obesity. Furthermore, the strain still has a weight reducing function after inactivation, thus having rich product mode, wide application range, high product stability and long preservation period.

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of human obesity protein (leptin) to result in leptin proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.

The invention provides methods and compositions for reducing the percentage of body fat in a mammal and/or the level of leptin in the bloodstream of the mammal. Such methods involve administering to the mammal a diet containing viscous polysaccharides.

The present disclosure provides compositions containing a leptin product and methods of clinical therapy and diagnostic methods for progressive cognitive disorders. According to one aspect, the described invention provides a method for treating a progressive cognitive disorder. According to another aspect, the described invention provides a method for improving resilience of cognitive function in a subject in need thereof. According to another aspect, the described invention provides a method for identifying an effective therapeutic agent for treating a progressive cognitive dysfunction disease or disorder that results from at least one of accumulation of Aβ, hyperphosphorylation of tau, or accumulation of neurofibrillary tangles.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling in the leptin-responsive cell. Administration of the peptide effectively prevents embryo implantation in a mammal to which the peptide has been administered. Also disclosed herein is a method for identifying a peptide antagonist of ObR, wherein the peptide comprises a leptin sequence.

The present invention relates to single nucleotide polymorphisms (SNPs) in the leptin promoter, and to methods for the identification of animals carrying specific alleles of these SNPs that are associated with circulating leptin levels, feed intake, growth rate, body weight, carcass merit and carcass composition. The present invention provides oligonucleotides that can be used as primers and/or probes to amplify and/or detect these SNPs, and provides methods for selecting and grouping animals, in particular bovines, according to genotype.

The invention provides a new leptin protein and the DNA sequence of the code thereof. The new leptin protein comes from cold-adaption animals-mice and rabbit families in extreme cold environment pressure. The invention lays the foundation for the protection, development and utilization of the leptin proteins of mice and rabbit family materials with Chinese characteristics and for the application in biological engineering products of mice and rabbit families.

Provided is an oil/fat composition comprising 10.1 to 94.9 wt. % of a triglyceride, 0.1 to 30 wt. % of a monoglyceride and 5 to 59.9 wt. % of a diglyceride which has, as a fatty acid constituent thereof, 15 to 90 wt. % of an ω3-unsaturated fatty acid having less than 20 carbon atoms. The oil/fat composition of the present invention has excellent heat stability, has body-fat-accumulation resisting action, visceral-fat-accumulation resisting action, blood-sugar-level lowering action, insulin resistance improving action and leptin lowering action and is useful for, as well as pharmaceuticals, preventive or remedial food for diabetes or obesity, and feed.

The invention relates to the field of microorganisms, in particular to a bifidobacterium animal and an application thereof in controlling diabetes or hyperlipidemia, particularly in weight gain or obesity. The preservation number of the bifidobacterium animal is CGMCC No.17308. The invention also discloses a product composition. The product composition contains thallus substances and/or metabolites of the bifidobacterium animal. The bifidobacterium animal provided by the invention is suitable for specific physiological physique of Chinese people, and has relatively high advantages in activityinhibition of alpha-glucosidase, transport inhibition of glucose, improvement of glucose tolerance level of organisms, relief of insulin resistance and leptin resistance, improvement of the secretionlevel of glucagon-like peptide-1, increase of islet cell size and islet beta cell number, and the like, so that development of diabetes or hyperlipidemia can be better controlled, and particularly weight gain and obesity of organisms can be controlled.

The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with a copper (II) halide; and (c) isolating the treated fusion molecule. The pharmacologically active compound can be an antibody or a fusion molecule comprising a pharmacologically active domain and an Fc domain. The preferred copper (II) halide is CuCl₂. The preferred concentration thereof is at least about 10 mM for fusion molecules prepared in E. coli; at least about 30 mM for fusion molecules prepared in CHO cells. The process can be employed with any number of pharmacologically active domains. Preferred pharmacologically active domains include OPG proteins, leptin proteins, soluble portions of TNF receptors (e.g., wherein the fusion molecule is etanercept), IL-1ra proteins, and TPO-mimetic peptides. The Fc domain preferably has a human sequence, with an Fc sequence derived from IgG1 most preferred. An exemplary Fc sequence is shown in FIG. 5 hereinafter.

The invention discloses a swine aphrodisiac powder preparation and its preparation technology and is characterized in that the swine aphrodisiac powder preparation comprises six traditional Chinese medicines as well as vitamin A, vitamin D3, vitamin E, biotin, organic chromium and a physiological activator (Leptin), wherein the six traditional Chinese medicines contain epimeddium, actinolite (quenched in wine), motherwort, Cyperus Rotundus L, Chinese angelica and Cuscuta sp. The preparation technology comprises the following steps of: carrying out superfine grinding on the six traditional Chinese medicines, stirring and mixing to obtain a traditional Chinese medicinal mixture, namely a master batch a; carrying out equivalent incremental mixing on vitamin A, vitamin D, vitamin E, biotin, organic chromium and the physiological activator (Leptin) by mixing for 10-20min each time, so as to obtain a master batch b; and mixing a and b for 25-35 min to obtain the swine aphrodisiac powder preparation. By the adoption of the swine aphrodisiac powder preparation, swine production performance and breeding rate can be fully raised.

The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.

The use of leptin and leptin-related molecules in oncology is disclosed.

A fibrin/fibrinogen binding conjugate for forming a depot for the sustained release of a pharmaceutically active substance from a fibrin clot. The conjugate comprises a fibrin/fibrinogen binding moiety bound to a pharmaceutically active substance either directly or via an intervening substance capturing moiety such as an antibody. The conjugate can also be a recombinant fusion protein comprising a fibrin/fibrinogen binding moiety such as VEGF165 C-terminal domain fused to a wound-healing substance such as leptin.